☆ 4.6 Article

Synergistic anticancer activity of combined ATR and ribonucleotide reductase inhibition in Ewing's sarcoma cells

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Biotechnology & Applied Microbiology

Targeting replication stress in cancer therapy

Alexandre Andre B. A. da Costa et al.

Summary: Replication stress is a major cause of genomic instability and a vulnerability of cancer cells. Inhibiting kinases such as ATR, CHK1, WEE1, and MYT1 can target this vulnerability. In addition, inhibiting the DNA damage response can elicit an immune response. Therefore, several inhibitors are being evaluated in clinical trials to overcome therapeutic resistance and promote antitumor immunity by targeting replication stress.

NATURE REVIEWS DRUG DISCOVERY (2023)

添加到收藏夹

Article Oncology

Molecularly Defined Subsets of Ewing Sarcoma Tumors Differ in Their Responses to IGF1R and WEE1 Inhibition

Upendra Kumar Soni et al.

Summary: This study analyzed the activation of receptor tyrosine kinase (RTK) pathway in Ewing sarcoma tumors and found that the tumors could be divided into two groups, one insensitive to IGF1R inhibition and the other sensitive to IGF1R or WEE1-targeted inhibitors. Primary and metastatic tumors also exhibited differences in IGF1R localization, replication stress levels, and inhibitor sensitivity. Combined inhibition of IGF1R and WEE1 led to tumor regression. These findings highlight the importance of using biopsy-derived predictive biomarkers at multiple stages of Ewing sarcoma disease management.

CLINICAL CANCER RESEARCH (2023)

添加到收藏夹

Review Oncology

Targeting DNA damage response pathways in cancer

Florian J. Groelly et al.

Summary: Cells have a complex network called the DNA damage response (DDR) to prevent detrimental mutations and coordinate DNA repair, cell-cycle checkpoint activation, and other cellular responses. Mutations in DDR genes are frequently found in cancer, causing genomic instability and influencing the tumor's response to DNA damage treatments. Tumors with mutated BRCA1 or BRCA2 are particularly susceptible to chemotherapeutic inhibitors of PARP, which has become a targeted therapy for cancer.

NATURE REVIEWS CANCER (2023)

添加到收藏夹

Review Oncology

Leveraging the replication stress response to optimize cancer therapy

Emily Cybulla et al.

Summary: This review describes the impact of DNA damage tolerance pathways on genome stability, their connection with tumorigenesis, and their effects on cancer therapy response. It discusses the accumulation of single-strand DNA gaps and its impact on chemotherapy response, as well as the potential of different DNA damage tolerance factors as cancer targets. The review also outlines how the consequences of DNA damage tolerance mechanisms could lead to the discovery of new biomarkers for refined cancer therapies.

NATURE REVIEWS CANCER (2023)

添加到收藏夹

Review Oncology

Target Actionability Review: a systematic evaluation of replication stress as a therapeutic target for paediatric solid malignancies

Kaylee M. Keller et al.

Summary: This study systematically reviewed the targeting of replication stress in pediatric tumors with a focus on DNA repair pathways and cell cycle checkpoint control. Various targets in these pathways have been studied in different diseases, with ATR, CHK1, PARP or WEE1 being the most promising targets in neuroblastoma, osteosarcoma, high-grade glioma or medulloblastoma.

EUROPEAN JOURNAL OF CANCER (2022)

添加到收藏夹

Article Oncology

High-Dose Treosulfan and Melphalan as Consolidation Therapy Versus Standard Therapy for High-Risk (Metastatic) Ewing Sarcoma

Raphael Koch et al.

Summary: The study evaluated the effect of high-dose chemotherapy followed by reinfusion of autologous hematopoietic stem cells on survival in high-risk Ewing sarcoma patients. The results showed no benefit of TreoMel-HDT for the entire cohort, but it may be beneficial for patients younger than 14 years. This observation is supported by other studies.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Review Oncology

Resistance to DNA repair inhibitors in cancer

Joseph S. Baxter et al.

Summary: The DNA damage response is a complex protein network that detects and repairs DNA damage, preventing cancer. PARP inhibitors are effective in treating cancer, and new DDR targets are being investigated. Drug resistance is a problem in cancer treatment, and there is some understanding of PARPi resistance.

MOLECULAR ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Long-term survival and cure fraction estimates for childhood cancer in Europe (EUROCARE-6): results from a population-based study

Laura Botta et al.

Summary: The EUROCARE-6 study analyzed data from 31 European countries and found disparities in childhood cancer survival rates among these countries. While the overall survival rates have improved for most cancer types, there are still differences in survival rates for specific cancers. The study also estimated the cure fraction for different childhood cancers and projected survival rates for the next 15 years.

LANCET ONCOLOGY (2022)

添加到收藏夹

Review Biochemistry & Molecular Biology

Review Hallmarks of DNA replication stress

Sneha Saxena et al.

Summary: Faithful DNA replication is crucial for maintaining genomic integrity. However, the replication process is constantly challenged by DNA damage and other stresses, collectively known as replication stress. Cells have evolved complex cellular responses to cope with replication stress and maintain genomic stability.

MOLECULAR CELL (2022)

添加到收藏夹

Review Oncology

Exploiting Replication Stress as a Novel Therapeutic Intervention

Jeffrey C. Martin et al.

Summary: Ewing sarcoma is an aggressive pediatric tumor with high levels of replication stress. The source of this stress is not well understood, but uncovering it may reveal novel therapeutic targets. Understanding the elevated replication stress in Ewing sarcoma could lead to the development of better treatment options.

MOLECULAR CANCER RESEARCH (2021)

添加到收藏夹

Review Medicine, General & Internal

Ewing's Sarcoma

Nicolo Riggi et al.

Summary: Ewing's sarcoma is an aggressive cancer that primarily affects children and young adults. In 85 to 90% of cases, a t(11;22) translocation is present. Treatment typically involves surgery, radiotherapy, and chemotherapy, with a 5-year survival rate of around 70%.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Cooperative treatment effectiveness of ATR and HSP90 inhibition in Ewing's sarcoma cells

Christian Marx et al.

Summary: The study suggests that combination treatment with HSP90 inhibitor and ATR inhibitor may be an effective therapeutic approach for Ewing's sarcoma, regardless of the p53 status.

CELL AND BIOSCIENCE (2021)

添加到收藏夹

Review Medicine, General & Internal

Ewing Sarcoma-Diagnosis, Treatment, Clinical Challenges and Future Perspectives

Stefan K. Zoellner et al.

Summary: Ewing sarcoma is a highly aggressive bone and soft-tissue cancer with a genetically simple yet specific therapeutic target. Current standard treatment involving systemic therapy and local treatment provides a realistic chance of cure for the majority of patients.

JOURNAL OF CLINICAL MEDICINE (2021)

添加到收藏夹

Article Oncology

Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumours

Mark R. Middleton et al.

Summary: The study demonstrated that berzosertib + gemcitabine is well tolerated in patients with advanced solid tumors and showed preliminary signs of efficacy. Berzosertib 210 mg/m(2) + gemcitabine 1000 mg/m(2) Q3W was established as the recommended Phase 2 dose.

BRITISH JOURNAL OF CANCER (2021)

添加到收藏夹

Article Oncology

TP53 mutations increase radioresistance in rhabdomyosarcoma and Ewing sarcoma

Dana L. Casey et al.

Summary: The study found that TP53 mutations are associated with decreased tumor control after radiation in patients with rhabdomyosarcoma and Ewing sarcoma. Alterations in the p53 pathway also contribute to inferior tumor control post radiation therapy.

BRITISH JOURNAL OF CANCER (2021)

添加到收藏夹

Letter Biochemistry & Molecular Biology

Translational evidence for RRM2 as a prognostic biomarker and therapeutic target in Ewing sarcoma

Shunya Ohmura et al.

MOLECULAR CANCER (2021)

添加到收藏夹

Review Oncology

Targeting the replication stress response through synthetic lethal strategies in cancer medicine

Natalie Y. L. Ngoi et al.

Summary: The replication stress response (RSR) is crucial for maintaining genomic integrity in the presence of elevated replicative stress, with increasing dependence of cancers on RSR. Drug candidates targeting key RSR nodes show promising efficacy in early phase trials, offering potential for overcoming PARP inhibitor resistance.

TRENDS IN CANCER (2021)

添加到收藏夹

Article Oncology

Inhibition of the ATR-CHK1 Pathway in Ewing Sarcoma Cells Causes DNA Damage and Apoptosis via the CDK2-Mediated Degradation of RRM2

Stacia L. Koppenhafer et al.

MOLECULAR CANCER RESEARCH (2020)

添加到收藏夹

Review Pharmacology & Pharmacy

Targeting ATR as Cancer Therapy: A new era for synthetic lethality and synergistic combinations?

Alice Bradbury et al.

PHARMACOLOGY & THERAPEUTICS (2020)

添加到收藏夹

Review Biochemistry & Molecular Biology

Biomarker-Guided Development of DNA Repair Inhibitors

James M. Cleary et al.

MOLECULAR CELL (2020)

添加到收藏夹

Review Biochemistry & Molecular Biology

Ribonucleotide Reductases: Structure, Chemistry, and Metabolism Suggest New Therapeutic Targets

Brandon L. Greene et al.

ANNUAL REVIEW OF BIOCHEMISTRY, VOL 89 (2020)

添加到收藏夹

Article Oncology

Anticancer effects of the PLK4 inhibitors CFI-400945 and centrinone in Ewing's sarcoma cells

Sophie L. Kerschner-Morales et al.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial

Panagiotis A. Konstantinopoulos et al.

LANCET ONCOLOGY (2020)

添加到收藏夹

Review Oncology

p53: 800 million years of evolution and 40 years of discovery

Arnold J. Levine

NATURE REVIEWS CANCER (2020)

添加到收藏夹

Review Pharmacology & Pharmacy

TP53 in bone and soft tissue sarcomas

Elizabeth Thoenen et al.

PHARMACOLOGY & THERAPEUTICS (2019)

添加到收藏夹

Article Multidisciplinary Sciences

Efficient apoptosis requires feedback amplification of upstream apoptotic signals by effector caspase-3 or -7

Scott McComb et al.

SCIENCE ADVANCES (2019)

添加到收藏夹

Article Oncology

The sirtuin 1/2 inhibitor tenovin-1 induces a nonlinear apoptosis-inducing factor-dependent cell death in a p53 null Ewing's sarcoma cell line

Christian Marx et al.

INVESTIGATIONAL NEW DRUGS (2018)

添加到收藏夹

Article Medicine, General & Internal

Ewing sarcoma

Thomas G. P. Gruenewald et al.

NATURE REVIEWS DISEASE PRIMERS (2018)

添加到收藏夹

Article Multidisciplinary Sciences

EWS-FLI1 increases transcription to cause R-loops and block BRCA1 repair in Ewing sarcoma

Aparna Gorthi et al.

NATURE (2018)

添加到收藏夹

Article Oncology

mTORC1/2 and Protein Translation Regulate Levels of CHK1 and the Sensitivity to CHK1 Inhibitors in Ewing Sarcoma Cells

Stacia L. Koppenhafer et al.

MOLECULAR CANCER THERAPEUTICS (2018)

添加到收藏夹

Article Hematology

Inhibition of ATR acutely sensitizes acute myeloid leukemia cells to nucleoside analogs that target ribonucleotide reductase

Sarah E. Fordham et al.

BLOOD ADVANCES (2018)

添加到收藏夹

Review Oncology

Targeting ATR in cancer

Emilio Lecona et al.

NATURE REVIEWS CANCER (2018)

添加到收藏夹

Review Oncology

Clinical pharmacology and clinical trials of ribonucleotide reductase inhibitors: is it a viable cancer therapy?

Mukundan Baskar Mannargudi et al.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2017)

添加到收藏夹

Review Biochemistry & Molecular Biology

Census and evaluation of p53 target genes

M. Fischer

ONCOGENE (2017)

添加到收藏夹

Article Oncology

Inhibition of ATR potentiates the cytotoxic effect of gemcitabine on pancreatic cancer cells through enhancement of DNA damage and abrogation of ribonucleotide reductase induction by gemcitabine

Shuang Liu et al.

ONCOLOGY REPORTS (2017)

添加到收藏夹

Article Oncology

Inhibition of CHK1 sensitizes Ewing sarcoma cells to the ribonucleotide reductase inhibitor gemcitabine

Kelli L. Goss et al.

ONCOTARGET (2017)

添加到收藏夹

Article Oncology

Reverse chemomodulatory effects of the SIRT1 activators resveratrol and SRT1720 in Ewing's sarcoma cells: resveratrol suppresses and SRT1720 enhances etoposide- and vincristine-induced anticancer activity

Juergen Sonnemann et al.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2016)

添加到收藏夹

Review Biochemistry & Molecular Biology

Mitochondria-Judges and Executioners of Cell Death Sentences

Patrick D. Bhola et al.

MOLECULAR CELL (2016)

添加到收藏夹

Article Oncology

Gene expression signature based screening identifies ribonucleotide reductase as a candidate therapeutic target in Ewing sarcoma

Kelli L. Goss et al.

ONCOTARGET (2016)

添加到收藏夹

Article Oncology

Efficacy of ATR inhibitors as single agents in Ewing sarcoma

Maria Nieto-Soler et al.

ONCOTARGET (2016)

添加到收藏夹

Article Oncology

RETRA exerts anticancer activity in Ewing's sarcoma cells independent of their TP53 status

Juergen Sonnemann et al.

EUROPEAN JOURNAL OF CANCER (2015)

添加到收藏夹

Review Biochemistry & Molecular Biology

Ribonucleotide reductase and cancer: biological mechanisms and targeted therapies

Y. Aye et al.

ONCOGENE (2015)

添加到收藏夹

Article Oncology

The Genomic Landscape of Pediatric Ewing Sarcoma

Brian D. Crompton et al.

CANCER DISCOVERY (2014)

添加到收藏夹

Article Oncology

Genomic Landscape of Ewing Sarcoma Defines an Aggressive Subtype with Co-Association of STAG2 and TP53 Mutations

Franck Tirode et al.

CANCER DISCOVERY (2014)

添加到收藏夹

Article Biochemistry & Molecular Biology

Cyclin F-Mediated Degradation of Ribonucleotide Reductase M2 Controls Genome Integrity and DNA Repair

Vincenzo D'Angiolella et al.

CELL (2012)

添加到收藏夹

Article Oncology

Anticancer effects of the p53 activator nutlin-3 in Ewing's sarcoma cells

Juergen Sonnemann et al.

EUROPEAN JOURNAL OF CANCER (2011)

添加到收藏夹

Article Biochemistry & Molecular Biology

Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR

Philip M. Reaper et al.

NATURE CHEMICAL BIOLOGY (2011)

添加到收藏夹

Article Oncology

Molecular Characterization of Commonly Used Cell Lines for Bone Tumor Research: A Trans-European EuroBoNet Effort

Laura Ottaviano et al.

GENES CHROMOSOMES & CANCER (2010)

添加到收藏夹

Article Oncology

Histone deacetylase inhibitors induce cell death and enhance the apoptosis-inducing activity of TRAIL in Ewing's sarcoma cells

Juergen Sonnemann et al.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2007)

添加到收藏夹

Review Pharmacology & Pharmacy

Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies

Ting-Chao Chou

PHARMACOLOGICAL REVIEWS (2006)

添加到收藏夹

Review Cell Biology

Do inducers of apoptosis trigger caspase-independent cell death?

JE Chipuk et al.

NATURE REVIEWS MOLECULAR CELL BIOLOGY (2005)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.